Net income: US$400.0m (up 13% from 2Q 2024). Profit margin: 0.7% (up from 0.6% in 2Q 2024). The increase in margin was driven ...

Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...

Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...

Cardinal Health Inc. closed 2.50% below its 52-week high of $131.00, which the company reached on January 27th.

Cardinal Health Inc. hit a new 52-week high, surpassing its previous peak of $129.68, which the company achieved on January ...

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.